Key facts
- Bayer CEO Bill Anderson said the $7.25 billion Roundup settlement could come any week now.
- Bayer faces approximately 65,000 claims in US state and federal courts over Roundup.
- Plaintiffs say they developed non-Hodgkin lymphoma and other cancers after using Roundup at home or on the job.
- Bayer moved its US Roundup business into a unit called Ruveon after a Supreme Court victory in June.
- Bayer has said decades of studies show glyphosate, Roundup's active ingredient, is safe and does not cause cancer.
Bayer expects a $7.25 billion settlement of its Roundup weedkiller litigation to come before Christmas, CEO Bill Anderson said on November 3. The proposed settlement, which the company is seeking in order to resolve tens of thousands of lawsuits, is under review by a Missouri state court judge in St. Louis.
"It could be any week now," Anderson said on a press call following the company's results, adding that there would be a much smaller number of individual cases after the settlement.
Bayer faces approximately 65,000 claims in US state and federal courts from plaintiffs who say they developed non-Hodgkin lymphoma and other forms of cancer after using Roundup at home or on the job. Bayer has said that decades of studies have shown glyphosate, Roundup's active ingredient, is safe and does not cause cancer.
Following a Supreme Court victory in June, Bayer moved its US Roundup business into a unit dubbed Ruveon and internally separated it from the rest of the organization.